BioCardia Inc. (BCDA), a clinical-stage regenerative medicine company, on Monday announced closing financing worth $4 million dollars.
The company sold 3,509,604 shares at an average price of $1.279 per share on June 5, 2026.
The proceeds of the financing were $4.4 million. The net proceeds are expected to extend cash runway into the first quarter of 2027.
The company is currently advancing CardiAMP, an allogenic cell therapy for the treatment of cardiovascular diseases and plans to submit an application for approval to the Japanese Pharmaceutical and Medical Devices Agency (PMDA) by the fourth quarter of 2026.
BCDA is currently trading at $0.96, down 6.57%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.